Overview of current and alternative therapies for idiopathic membranous nephropathy

Pharmacotherapy

Volumn 35, Issue 4, 2015, Pages 396-411

  Tran, Tran H ^a,b   Hughes, Gregory J ^a   Greenfeld, Chuck ^c   Pham, Jacqueline T ^c  

^a ST JOHN'S UNIVERSITY   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

adrenocorticotropic hormone; azathioprine; idiopathic membranous nephropathy; intravenous immunoglobulin; membranous; mycophenolate mofetil; rituximab

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOTROPIN; CYCLOSPORIN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT;

ALTERNATIVE MEDICINE; ANGIONEUROTIC EDEMA; CHILL; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; HIGH RISK PATIENT; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IDIOPATHIC DISEASE; INFECTION; KIDNEY DISEASE; LARYNX SPASM; MEMBRANOUS GLOMERULONEPHRITIS; MYALGIA; NEPHROTOXICITY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENT DISEASE; REVIEW; TREATMENT DURATION; TREATMENT REFUSAL; CLINICAL TRIAL (TOPIC); GLOMERULONEPHRITIS, MEMBRANOUS; IMMUNOLOGY;

CLINICAL TRIALS AS TOPIC; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECURRENCE;

EID: 84927730786     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1575     Document Type: Review

References (54)

1. Beck LH, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21.
2. Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011; 364: 616-26.
3. Chen Y, Schieppati A, Cai G, et al. Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials. Clin J Am Soc Nephrol 2013; 8: 787-96.
4. Van den Brand JAJG, van Dijk PR, Hofstra JM, Wetzels JFM,. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol 2014; 25: 150-8.
5. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2012; 2 (Suppl.): 139-274.
6. Beck L, Bomback AS, Choi MJ, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 2013; 62: 403-41.
7. Ponticelli C, Zucchelli P, Passerini P, Cesana B,. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. N Engl J Med 1992a; 327: 599-603.
8. Ponticelli C, Zucchelli P, Imbasciati E, et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1984; 310: 946-50.
9. Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9: 444-50.
10. Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007; 18: 1899-904.
11. Elkhalifa AS, Weiner HL,. Cyclophosphamide treatment of MS: current therapeutic approaches and treatment regimens. Int MS J 2010; 17: 12-8.
12. McQuarrie EP, Stirling CM, Geddes CC,. Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy. Nephrol Dial Transplant 2012; 27: 235-42.
13. Van den Brand JAJG, van Dijk PR, Hofstra JM, Wetzels JFM,. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2014; 9: 1066-73.
14. Robak E, Robak T,. Novel and emerging drugs for systemic lupus erythematosus: mechanism of action and therapeutic activity. Curr Med Chem 2012; 19: 438-53.
15. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14: 931-8.
16. Chen M, Li H, Li XY, et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci 2010; 339: 233-8.
17. Guasch A, Suranyi M, Newton L, Hall BM, Myers BD,. Short-term responsiveness of membranous glomerulopathy to cyclosporine. Am J Kidney Dis 1992; 20: 472-81.
18. Praga M, Barrio V, Fernandez Juarez G, Luño J,. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 2007; 71: 924-30.
19. Cattran DC, Greenwood C, Ritchie S, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 1995; 47: 1130-5.
20. Coban M, Eke RN, Kizilates F, Ucar S, Dede F,. Effect of steroid and cyclosporine in membranous nephropathy that is resistant to steroid and/or cytotoxic treatment. Int J Clin Exp Med 2014; 7: 255-61.
21. Howman A, Chapman TL, Langdon MM, et al. Immunosuppression for progressive membranous nephropathy: a UK randomized controlled trial. Lancet 2013; 381: 744-51.
22. Genetech USA, Inc. Rituxan (rituximab) package insert. San Francisco, CA; 2013.
23. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P,. Rituximab for idiopathic membranous nephropathy. Lancet 2002; 360: 923-4. Erratum in: Lancet 2002 Dec 21-28;360(9350):2090.
24. Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003; 14: 1851-7.
25. Ruggenenti P, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 2006; 1: 738-48.
26. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G,. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007; 2: 932-7.
27. Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23: 1416-25.
28. Cravedi P, Sghirlanzoni MC, Marasà M, Salerno A, Remuzzi G, Ruggenenti P,. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol 2011; 33: 461-8.
29. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73: 117-25.
30. Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010; 5: 2188-98.
31. Segarra A, Praga M, Ramos N, et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009; 4: 1083-8.
32. Genetech USA, Inc. CellCept (mycophenolate mofetil) package insert. San Francisco, CA; 2012.
33. Chan TM, Lin AW, Tang SC, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology 2007; 12: 576.
34. Senthil Nayagam L, Ganguli A, Rathi M, et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 2008; 23: 1926.
35. Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF,. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 2007; 50: 248.
36. Dussol B, Morange S, Burtey S, et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis 2008; 52: 699.
37. Miller G, Zimmerman R 3rd, Radhakrishnan J, Appel G,. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000; 36: 250.
38. Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61: 1098.
39. Rapoport M, McCrory WW, Barbero G, Barnett HL, Forman CW,. Effect of corticotropin (ACTH) on children with the nephrotic syndrome. J Am Med Assoc 1951; 147: 1101-6.
40. Barnett HL,. Effect of ACTH in children with the nephrotic syndrome. Pediatrics 1952; 9: 341.
41. Mallinckrodt Pharmaceuticals (formerly Questcor). H.P. Acthar Gel (repository corticotropin injection) package insert. Hayward, CA.
42. Lindskog A, Ebefors K, Johansson ME, et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol 2010; 21: 1290-8.
43. Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006; 47: 233.
44. Bomback AS, Radhakrishnan J,. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH). Discov Med 2011; 12: 91-6.
45. Bomback AS, Canetta PA, Beck LH Jr, Ayalon R, Radhakrishnan J, Appel GB,. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol 2012; 36: 58-67.
46. Besser GM, Butler PW, Plumpton FS,. Adrenocorticotrophic action of long-acting tetracosactrin compared with corticotrophin-gel. Br Med J 1967; 4: 391-4.
47. Gong R,. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol 2012; 8: 122-8.
48. Hladunewich MA, Cattran D, Beck LH, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transplant 2014; 8: 1570-7.
49. Palla R, Cirami C, Panichi V, Bianchi AM, Parrini M, Grazi G,. Intravenous immunoglobulin therapy of membranous nephropathy: efficacy and safety. Clin Nephrol 1991; 35: 98-104.
50. Monova D, Belovezhdov N, Altunkova I, Monov S,. Intravenous immunoglobulin G in the treatment of patients with chronic glomerulonephritis: clinical experience lasting 15 years. Nephron 2002; 90: 262-6.
51. Yokoyama H, Goshima S, Wada T, et al. The short- and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy. Kanazawa Study Group for Renal Diseases and Hypertension. Nephrol Dial Transplant 1999; 14: 2379-86.
52. Naumovic R, Jovanovic D, Pavlovic S, et al. Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: a 3-year prospective study. Biomed Pharmacother 2011; 65: 105-10.
53. Goumenos DS, Ahuja M, Davlouros P, et al. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study. Clin Nephrol 2006; 65: 317.
54. Ahuja M, Goumenos D, Shortland JR, et al. Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy? Am J Kidney Dis 1999; 34: 521.